Structural highlights
Publication Abstract from PubMed
Antimycins are anticancer compounds produced by a hybrid nonribosomal peptide synthetase/polyketide synthase (NRPS/PKS) pathway. The biosynthesis of these compounds is well characterized, with the exception of the standalone beta-ketoreductase enzyme AntM that is proposed to catalyze the reduction of the C8 carbonyl of the antimycin scaffold. Inactivation of antM and structural characterization suggested that rather than functioning as a post-PKS tailoring enzyme, AntM acts upon the terminal biosynthetic intermediate while it is tethered to the PKS acyl carrier protein. Mutational analysis identified two amino acid residues (Tyr185 and Phe223) that are proposed to serve as checkpoints controlling substrate access to the AntM active site. Aromatic checkpoint residues are conserved in uncharacterized standalone beta-ketoreductases, indicating that they may also act concomitantly with synthesis of the scaffold. These data provide novel mechanistic insights into the functionality of standalone beta-ketoreductases and will enable their reprogramming for combinatorial biosynthesis.
Standalone beta-Ketoreductase Acts Concomitantly with Biosynthesis of the Antimycin Scaffold.,Fazal A, Hemsworth GR, Webb ME, Seipke RF ACS Chem Biol. 2021 Jun 20. doi: 10.1021/acschembio.1c00229. PMID:34151573[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Fazal A, Hemsworth GR, Webb ME, Seipke RF. Standalone beta-Ketoreductase Acts Concomitantly with Biosynthesis of the Antimycin Scaffold. ACS Chem Biol. 2021 Jun 20. doi: 10.1021/acschembio.1c00229. PMID:34151573 doi:http://dx.doi.org/10.1021/acschembio.1c00229
